François Maillet, Jacques-Emmanuel Galimard, Raphaël Borie, Elodie Lainey, Lise Larcher, Marie Passet, Aurélie Plessier, Thierry Leblanc, Louis Terriou, Delphine Lebon, Vincent Alcazer, Pascal Cathebras, Michael Loschi, Abou-Chahla Wadih, Ambroise Marcais, Alice Marceau-Renaut, Nathalie Couque, Bruno Lioure, Jean Soulier, Ibrahima Ba, Gérard Socié, Regis Peffault de Latour, Caroline Kannengiesser, Flore Sicre de Fontbrune
Data on haematological features of telomere biology disorders (TBD) remain scarce. We describe haematological, extra-haematological characteristics and prognosis of 127 genetically confirmed TBD patients diagnosed after the age of 15. Ninety-three index cases and 34 affected relatives were included. At diagnosis of TBD, 76.3% of index cases had haematological features, half pulmonary features and a third liver features. At diagnosis, bone marrow failure (BMF) was present in 59 (46.5%), myelodysplastic syndrome (MDS) in 22 (17.3%) and acute myeloid leukaemia (AML) in 2 (1.6%) while 13 (10.2%) developed or worsened bone marrow involvement during follow-up. At diagnosis, compared to MDS/AML patients, BMF patients were younger (median 23.1 years vs. 43.8, p = 0.007), and had a better outcome (4-year overall survival 76.3% vs. 31.8%, p < 0.001). While frequencies and burden of cytogenetical and somatic mutations increased significantly in myeloid malignancies, some abnormalities were also observed in patients with normal blood counts and BMF, notably somatic spliceosome variants. Solid cancers developed in 8.7% patients, mainly human papillomavirus-related cancers and hepatocellular carcinomas. TBD is a multiorgan progressive disease. While BMF is the main haematological disorder, high-risk myeloid malignancies are common, and are, together with age, the only factors associated with a worse outcome.
{"title":"Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.","authors":"François Maillet, Jacques-Emmanuel Galimard, Raphaël Borie, Elodie Lainey, Lise Larcher, Marie Passet, Aurélie Plessier, Thierry Leblanc, Louis Terriou, Delphine Lebon, Vincent Alcazer, Pascal Cathebras, Michael Loschi, Abou-Chahla Wadih, Ambroise Marcais, Alice Marceau-Renaut, Nathalie Couque, Bruno Lioure, Jean Soulier, Ibrahima Ba, Gérard Socié, Regis Peffault de Latour, Caroline Kannengiesser, Flore Sicre de Fontbrune","doi":"10.1111/bjh.19767","DOIUrl":"https://doi.org/10.1111/bjh.19767","url":null,"abstract":"<p><p>Data on haematological features of telomere biology disorders (TBD) remain scarce. We describe haematological, extra-haematological characteristics and prognosis of 127 genetically confirmed TBD patients diagnosed after the age of 15. Ninety-three index cases and 34 affected relatives were included. At diagnosis of TBD, 76.3% of index cases had haematological features, half pulmonary features and a third liver features. At diagnosis, bone marrow failure (BMF) was present in 59 (46.5%), myelodysplastic syndrome (MDS) in 22 (17.3%) and acute myeloid leukaemia (AML) in 2 (1.6%) while 13 (10.2%) developed or worsened bone marrow involvement during follow-up. At diagnosis, compared to MDS/AML patients, BMF patients were younger (median 23.1 years vs. 43.8, p = 0.007), and had a better outcome (4-year overall survival 76.3% vs. 31.8%, p < 0.001). While frequencies and burden of cytogenetical and somatic mutations increased significantly in myeloid malignancies, some abnormalities were also observed in patients with normal blood counts and BMF, notably somatic spliceosome variants. Solid cancers developed in 8.7% patients, mainly human papillomavirus-related cancers and hepatocellular carcinomas. TBD is a multiorgan progressive disease. While BMF is the main haematological disorder, high-risk myeloid malignancies are common, and are, together with age, the only factors associated with a worse outcome.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily Durity, Jiexin Zheng, Emilie Sanchez, Matthew Donati, Keith Perry, Jade Derrick, Andy Taylor, Colin Fink, Jennifer Holden, Paul Grant, Matt Byott, William Rickaby, Nathan Asher, Stephen L Walker, Kirsty Thomson, Chris Bunker
{"title":"Novel finding of vaccine-derived rubella virus-associated granulomata in an adult patient post-allogeneic haematopoietic stem cell transplant.","authors":"Emily Durity, Jiexin Zheng, Emilie Sanchez, Matthew Donati, Keith Perry, Jade Derrick, Andy Taylor, Colin Fink, Jennifer Holden, Paul Grant, Matt Byott, William Rickaby, Nathan Asher, Stephen L Walker, Kirsty Thomson, Chris Bunker","doi":"10.1111/bjh.19762","DOIUrl":"https://doi.org/10.1111/bjh.19762","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Cicconi, Marialaura Bisegna, Carmelo Gurnari, David Fanciullo, Alfonso Piciocchi, Giovanni Marsili, Clara Minotti, Emilia Scalzulli, Bianca Mandelli, Luca Guarnera, Salvatore Perrone, Elettra Ortu La Barbera, Sergio Mecarocci, Annalisa Biagi, Natalia Cenfra, Andrea Corbingi, Maria Cristina Scerpa, Adriano Venditti, Maurizio Martelli, Maria Teresa Voso, Massimo Breccia, Alessandro Pulsoni
SummaryAll‐trans‐retinoic acid (ATRA) and arsenic trioxide (ATO) represent the standard of care for low‐intermediate risk acute promyelocytic leukaemia (APL). Leucocytosis during induction with ATRA‐ATO represents a common complication with an incidence of up to 60%. To identify predictive factors for this complication, we studied a cohort of 65 low‐intermediate risk APL patients treated with ATRA‐ATO in three highly specialized Italian centres. Overall, 39/65 (60%) patients developed leucocytosis, with a peak in leucocyte count being most frequent in the second week from diagnosis. All cases were successfully managed with hydroxyurea. Predictive factors for leucocytosis in univariate analysis were lower platelet counts (odds ratio [OR] 0.98, 0.97–1.00, p = 0.018), lower fibrinogen levels (OR 0.36, 0.17–0.66, p = 0.003), higher bone marrow blast infiltration (OR 1.03, 1.01–1.07, p = 0.021) and CD117 expression by flow (OR 1.04, 1.01–1.08, p = 0.012). Multivariate analysis confirmed lower levels of fibrinogen at diagnosis as the strongest predictive factor for the development of leucocytosis (OR 0.36, 0.15–0.72, p = 0.009). Differentiation syndrome (DS) occurred only in patients developing leucocytosis showing a strict correlation with rising leucocytes counts (16/39 vs. 0/26, p < 0.001). In addition, other treatment‐related complications including QTc prolongation, cardiac events, liver, and haematological toxicities were significantly more frequent in patients experiencing leucocytosis (22/39 vs. 3/26, p < 0.001). In conclusion, APL patients undergoing ATRA‐ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment‐related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications.
{"title":"Leucocytosis during induction therapy with all‐trans‐retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment‐related complications","authors":"Laura Cicconi, Marialaura Bisegna, Carmelo Gurnari, David Fanciullo, Alfonso Piciocchi, Giovanni Marsili, Clara Minotti, Emilia Scalzulli, Bianca Mandelli, Luca Guarnera, Salvatore Perrone, Elettra Ortu La Barbera, Sergio Mecarocci, Annalisa Biagi, Natalia Cenfra, Andrea Corbingi, Maria Cristina Scerpa, Adriano Venditti, Maurizio Martelli, Maria Teresa Voso, Massimo Breccia, Alessandro Pulsoni","doi":"10.1111/bjh.19759","DOIUrl":"https://doi.org/10.1111/bjh.19759","url":null,"abstract":"SummaryAll‐<jats:italic>trans</jats:italic>‐retinoic acid (ATRA) and arsenic trioxide (ATO) represent the standard of care for low‐intermediate risk acute promyelocytic leukaemia (APL). Leucocytosis during induction with ATRA‐ATO represents a common complication with an incidence of up to 60%. To identify predictive factors for this complication, we studied a cohort of 65 low‐intermediate risk APL patients treated with ATRA‐ATO in three highly specialized Italian centres. Overall, 39/65 (60%) patients developed leucocytosis, with a peak in leucocyte count being most frequent in the second week from diagnosis. All cases were successfully managed with hydroxyurea. Predictive factors for leucocytosis in univariate analysis were lower platelet counts (odds ratio [OR] 0.98, 0.97–1.00, <jats:italic>p</jats:italic> = 0.018), lower fibrinogen levels (OR 0.36, 0.17–0.66, <jats:italic>p</jats:italic> = 0.003), higher bone marrow blast infiltration (OR 1.03, 1.01–1.07, <jats:italic>p</jats:italic> = 0.021) and CD117 expression by flow (OR 1.04, 1.01–1.08, <jats:italic>p</jats:italic> = 0.012). Multivariate analysis confirmed lower levels of fibrinogen at diagnosis as the strongest predictive factor for the development of leucocytosis (OR 0.36, 0.15–0.72, <jats:italic>p</jats:italic> = 0.009). Differentiation syndrome (DS) occurred only in patients developing leucocytosis showing a strict correlation with rising leucocytes counts (16/39 vs. 0/26, <jats:italic>p</jats:italic> < 0.001). In addition, other treatment‐related complications including QTc prolongation, cardiac events, liver, and haematological toxicities were significantly more frequent in patients experiencing leucocytosis (22/39 vs. 3/26, <jats:italic>p</jats:italic> < 0.001). In conclusion, APL patients undergoing ATRA‐ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment‐related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Given the significant limitations of available literature, central nervous system (CNS) prophylaxis in large B‐cell lymphomas remains debatable. Wilson and colleagues provide cautious recommendations, on a case‐by‐case basis, useful to guide discussion with individual patient. In daily practice, CNS relapse risk, prophylaxis safety and prognosis of CNS recurrence must be considered.Commentary on: Wilson et al. Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19686.
鉴于现有文献的巨大局限性，大 B 细胞淋巴瘤的中枢神经系统（CNS）预防仍存在争议。威尔逊及其同事根据具体情况提出了谨慎的建议，有助于指导与患者的讨论。在日常实践中，必须考虑中枢神经系统复发风险、预防安全性和中枢神经系统复发的预后：Wilson等人.大B细胞淋巴瘤的中枢神经系统预防：英国血液学会良好实践论文。Br J Haematol 2024（在线提前打印）。doi: 10.1111/bjh.19686.
{"title":"CNS prophylaxis in large B‐cell lymphomas: A balance with three pans","authors":"Teresa Calimeri, Andrés J. M. Ferreri","doi":"10.1111/bjh.19774","DOIUrl":"https://doi.org/10.1111/bjh.19774","url":null,"abstract":"Given the significant limitations of available literature, central nervous system (CNS) prophylaxis in large B‐cell lymphomas remains debatable. Wilson and colleagues provide cautious recommendations, on a case‐by‐case basis, useful to guide discussion with individual patient. In daily practice, CNS relapse risk, prophylaxis safety and prognosis of CNS recurrence must be considered.Commentary on: Wilson et al. Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper. Br J Haematol 2024 (Online ahead of print). doi: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"https://doi.org/10.1111/bjh.19686\">10.1111/bjh.19686</jats:ext-link>.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Lebreton, F. Lachenal, S. Bouillie, G. M. Pica, H. Aftisse, L. Pascal, L. Montes, M. Macro, N. Johnson, S. Harel, M. Fernandez, B. De Renzis, B. Lioure, A. Lazareth, M. Javelot, C. Louni, A. Huart, A. Perrot
{"title":"Teclistamab for relapsed refractory multiple myeloma patients on dialysis","authors":"P. Lebreton, F. Lachenal, S. Bouillie, G. M. Pica, H. Aftisse, L. Pascal, L. Montes, M. Macro, N. Johnson, S. Harel, M. Fernandez, B. De Renzis, B. Lioure, A. Lazareth, M. Javelot, C. Louni, A. Huart, A. Perrot","doi":"10.1111/bjh.19772","DOIUrl":"https://doi.org/10.1111/bjh.19772","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Natasha Burke, Vaishali Sanchorawala
SummaryPatients with AL amyloidosis can have persistent organ dysfunction despite achieving a haematological complete response (hemCR). We aimed to identify factors for organ non‐response among 143 patients who achieved hemCR for ≥6 months. Kidney, heart and liver non‐response were observed in 40/117 (34%), 19/68 (28%) and 3/17 (18%) patients respectively. Predisposing factors varied by organ system. Kidney non‐responders had more advanced organ dysfunction at diagnosis, whereas heart non‐responders had disproportionately more lambda‐typic amyloidogenic light chains. Most patients without an apparent reason for organ non‐response had detectable residual clonal disease. The interplay of factors impeding organ recovery in AL amyloidosis is complex.
{"title":"Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis","authors":"Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Natasha Burke, Vaishali Sanchorawala","doi":"10.1111/bjh.19766","DOIUrl":"https://doi.org/10.1111/bjh.19766","url":null,"abstract":"SummaryPatients with AL amyloidosis can have persistent organ dysfunction despite achieving a haematological complete response (hemCR). We aimed to identify factors for organ non‐response among 143 patients who achieved hemCR for ≥6 months. Kidney, heart and liver non‐response were observed in 40/117 (34%), 19/68 (28%) and 3/17 (18%) patients respectively. Predisposing factors varied by organ system. Kidney non‐responders had more advanced organ dysfunction at diagnosis, whereas heart non‐responders had disproportionately more lambda‐typic amyloidogenic light chains. Most patients without an apparent reason for organ non‐response had detectable residual clonal disease. The interplay of factors impeding organ recovery in AL amyloidosis is complex.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
SummaryThe efficacy and safety of recombinant human thrombopoietin (rhTPO) in children and adolescent patients with chronic primary immune thrombocytopenia (ITP) remains unclear. A multicentre, randomized, double‐blind, placebo‐controlled phase III trial was performed. Patients aged 6–17 years, diagnosed with ITP and resistant or relapsed to corticosteroid treatment were included. For the trial, part 1 was exploratory and part 2 was the main analysis, with part 1 determining whether part 2 was stratified by age. Patients in part 1 were treated with rhTPO (the 6‐ to 11‐/12‐ to 17‐year‐old groups; 1:1). Patients in part 2 were randomized (3:1) to receive either rhTPO treatment or placebo. Patients received rhTPO or placebo at a dose of 300 U/kg once daily for up to 14 days. A total of 68 patients were included [part 1 (12 patients), part 2 (56 patients)]. The total response rate (TRR) in part 1 was 50.0% (95% CI: 21.09%–78.91%). For part 2, the TRR was 58.5% (95% CI: 42.11%–73.68%) and 13.3% (95% CI: 1.66%–40.46%) in the rhTPO and placebo groups (FAS) respectively. The difference in TRR between the rhTPO group and placebo group was 45.2% (95% CI: 22.33%–68.08%) and 44.6% (95% CI: 21.27%–67.85%) on the FAS and per‐protocol set (PPS), respectively, which indicates the superiority of rhTPO treatment.
{"title":"Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double‐blind, placebo‐controlled phase III trial","authors":"Jingyao Ma, Xiaoli Zhang, Libo Zhao, Xiaoyan Wu, Yanhua Yao, Wei Liu, Xiaohuan Wang, Xiuli Ju, Xiaodong Shi, Lirong Sun, Lili Zheng, Shu Liu, Jun Qian, Runhui Wu","doi":"10.1111/bjh.19761","DOIUrl":"https://doi.org/10.1111/bjh.19761","url":null,"abstract":"SummaryThe efficacy and safety of recombinant human thrombopoietin (rhTPO) in children and adolescent patients with chronic primary immune thrombocytopenia (ITP) remains unclear. A multicentre, randomized, double‐blind, placebo‐controlled phase III trial was performed. Patients aged 6–17 years, diagnosed with ITP and resistant or relapsed to corticosteroid treatment were included. For the trial, part 1 was exploratory and part 2 was the main analysis, with part 1 determining whether part 2 was stratified by age. Patients in part 1 were treated with rhTPO (the 6‐ to 11‐/12‐ to 17‐year‐old groups; 1:1). Patients in part 2 were randomized (3:1) to receive either rhTPO treatment or placebo. Patients received rhTPO or placebo at a dose of 300 U/kg once daily for up to 14 days. A total of 68 patients were included [part 1 (12 patients), part 2 (56 patients)]. The total response rate (TRR) in part 1 was 50.0% (95% CI: 21.09%–78.91%). For part 2, the TRR was 58.5% (95% CI: 42.11%–73.68%) and 13.3% (95% CI: 1.66%–40.46%) in the rhTPO and placebo groups (FAS) respectively. The difference in TRR between the rhTPO group and placebo group was 45.2% (95% CI: 22.33%–68.08%) and 44.6% (95% CI: 21.27%–67.85%) on the FAS and per‐protocol set (PPS), respectively, which indicates the superiority of rhTPO treatment.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aurore Vanden Bulcke, Bérénice Tiquet, Stefania Magnoni, Nicolas Mongardon
{"title":"A shock with skin necrosis is not always necrotising soft tissue infection","authors":"Aurore Vanden Bulcke, Bérénice Tiquet, Stefania Magnoni, Nicolas Mongardon","doi":"10.1111/bjh.19718","DOIUrl":"https://doi.org/10.1111/bjh.19718","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Nizar Abdel Samad, Stephane Doucet, Jill Dudebout, Isabelle Fleury, Graeme Fraser, Jean‐Francois Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Ryan D. Morin, Miguel Alcaide, Susana Ben‐Neriah, David Lee, Chad Winch, Lois E. Shepherd, David W. Scott, Michael Crump, Bingshu E. Chen, Annette E. Hay
{"title":"A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma","authors":"John Kuruvilla, Christopher Rushton, Diego Villa, Muhammad Aslam, Anca Prica, Nizar Abdel Samad, Stephane Doucet, Jill Dudebout, Isabelle Fleury, Graeme Fraser, Jean‐Francois Larouche, Mona Shafey, Pamela Skrabek, Tanya Skamene, Ryan D. Morin, Miguel Alcaide, Susana Ben‐Neriah, David Lee, Chad Winch, Lois E. Shepherd, David W. Scott, Michael Crump, Bingshu E. Chen, Annette E. Hay","doi":"10.1111/bjh.19764","DOIUrl":"https://doi.org/10.1111/bjh.19764","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haemophagocytic lymphohistiocytosis (HLH) that occurs concomitantly with leukaemia can be initially missed due to overlapping clinical features. In a series of three cases, Tanabe and colleagues illustrate the need for prompt recognition of HLH and institution of HLH‐directed therapy to prevent hyperinflammation‐mediated multi‐organ damage and death.Commentary on: Tanabe et al. Paediatric acute lymphoblastic leukaemia‐associated haemophagocytic lymphohistiocytosis develops during prednisolone prephase. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19755.
与白血病同时发生的嗜血细胞淋巴组织细胞增多症（HLH）最初可能因临床特征重叠而被漏诊。Tanabe及其同事在三个病例中说明了及时识别HLH并进行HLH定向治疗的必要性，以防止高炎症介导的多器官损伤和死亡：Tanabe等人.儿科急性淋巴细胞白血病相关嗜血细胞淋巴组织细胞增多症在泼尼松龙前期发展.Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19755.
{"title":"Incorrigible inflammation","authors":"Hany Ariffin","doi":"10.1111/bjh.19773","DOIUrl":"https://doi.org/10.1111/bjh.19773","url":null,"abstract":"Haemophagocytic lymphohistiocytosis (HLH) that occurs concomitantly with leukaemia can be initially missed due to overlapping clinical features. In a series of three cases, Tanabe and colleagues illustrate the need for prompt recognition of HLH and institution of HLH‐directed therapy to prevent hyperinflammation‐mediated multi‐organ damage and death.Commentary on: Tanabe et al. Paediatric acute lymphoblastic leukaemia‐associated haemophagocytic lymphohistiocytosis develops during prednisolone prephase. Br J Haematol 2024 (Online ahead of print). doi: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"https://doi.org/10.1111/bjh.19755\">10.1111/bjh.19755</jats:ext-link>.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":6.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号